Milda RUDZIANSKIENE, ARTURAS INCIURA, ELONA JUOZAITYTE, Rolandas GERBUTAVICIUS, Renata SIMOLIUNIENE, Viktoras RUDZIANSKAS, Greta Emilia KIAVIALAITIS

The impact of one fraction of 8 Gy radiotherapy in palliative treatment of multiple myeloma patients with painful bone destructions

Background/aim: Radiotherapy is required to overcome pain and to promote recalcification in multiple myeloma (MM) patients. The aim of our prospective study was to evaluate the impact of one fraction of 8 Gy regimen in palliative treatment of MM. Materials and methods: Forty-six patients with MM and painful bone destructions were treated by 8 Gy single fraction regimen. The visual analog scale was used for evaluation of pain. Analgesic use was measured prior to and after radiotherapy (4, 12, and 24 weeks). Recalcification was evaluated with radiographs before and after radiotherapy at 1 and 3 months. Quality of life questionnaires were completed before and 4 weeks after treatment. Results: Decrease of pain was observed in 78.3% cases: according to the international consensus on palliative radiotherapy criteria, 43.5% were found to be completely and 34.8% partially responsive. Reduction of analgesic use was present in 68.4% and complete cessation in 31.6%. Recalcification was present in 55%: a complete response was observed in 35% and a partial response in 20%. The side effects after treatment were of the first grade and reversible. Conclusion: One fraction of 8 Gy regimen is effective in palliative treatment of MM patients with painful bone destructions.

Anahtar Kelimeler:

Multiple myeloma, pain relief, radiotherapy, recalcification

The impact of one fraction of 8 Gy radiotherapy in palliative treatment of multiple myeloma patients with painful bone destructions

Keywords:

Multiple myeloma, pain relief, radiotherapy, recalcification,

PDF

___

Kyle RA, Rajkumer SV. Multiple myeloma. Blood 2008; 111: 2962–2972.
Yeh HS, Berenson JR. Myeloma bone disease and treatment options. Eur J Cancer 2006; 42: 1554–1563. 3. Stolting T, Knauerhase H, Klautke G, Kundt G, Frietkau R. Total and single doses influence the effectiveness of radiotherapy in palliative treatment of plasmacytoma. Strahlenther Onkol 2008; 184: 465–472.
Adamietz IA, Schober C, Schulte RW, Peest D, Renner K. Palliative radiotherapy in plasma cell myeloma. Radiother Oncol 1991; 20: 111–116. 5. Bosch A, Frias Z. Radiotherapy in the treatment of the multiple myeloma. Int J Radiat Oncol Biol Phys 1988; 15: 1363–1369.
Leigh BR, Kurtts TA, Curtis FM, Matzner MB, Shimm DS. Radiation therapy for the palliation of multiple myeloma. Int J Radiat Oncol Biol Phys 1993; 25: 801–804. 7. Minowa Y, Sasai K, Ishigaki T, Nagata Y, Hiraoka M. Palliative radiation therapy for multiple myeloma. Nippon Igaku Hoshasen Gakkai Zasshi 1996; 56: 1056–1060.
Mose S, Pfitzner D, Rahn A, Nierhoff C, Schiemann M, Bottcher HD. Wertigkeit der Radiologie in der Behandlung des multiplen Myeloms. Strahlenther Oncol 2000; 176: 506–512 (in German).
Mill WB, Griffith R. The role of radiation therapy in the management of plasma cell tumours. Cancer 1980; 45: 647– 652.
Hu K, Yahalom J. Radiotherapy in the management of plasma cell tumors. Oncology (Williston Park) 2000; 14: 101–108.
Liebros RH, Ha CS, Cox JD. Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. Int J Radiat Oncol Biol Phys 1998; 441: 1063–1067.
Norin T. Roentgen treatment of myeloma with special consideration to the dosage. Acta Radiol 1957; 47: 46–54.
Balducci M, Chiesa S, Manfrida S, Rossi E, Za T, Frascino V, De Bari B, Hohaus S, Cellini F, Mantini G et al. Impact of radiotherapy on pain relief and recalcification in plasma cell neoplasms: long-term experience. Strahlenther Onkol 2011; 187: 114–119.
Price P, Hoskin PJ, Easton D, Austin D, Palmer SG, Yarnold JR. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. Radiother Oncol 1986; 6: 247–255.
Foro P, Algara M, Reig A, Lacruz M, Valls A. Randomized prospective trial comparing three schedules of palliative radiotherapy: preliminary results. Oncologia 1998; 21: 55–60.
Koswig S, Budach V. Remineralization and pain relief in bone metastases after different radiotherapy fractions (10 times 3 Gy vs. 1 time 8 Gy). A prospective study. Strahlenther Onkol 1999; 175: 500–508.
Bone Pain Trial Working Party. 8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomized comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party. Radiother Oncol 1999; 52: 111–121.
Ozsaran Z, Yalman D, Anacek Y. Palliative radiotherapy in bone metastases: Results of a randomized trial comparing three fractionation schedules. J Balkan Union Oncol 2001; 6: 43–48.
Hartsell WF, Scott CB, Burner DW, Scarantino CW, Ivker RA, Roach M 3rd, Suh JH, Demas WF, Movsas B, Petersen IA et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005; 97: 798–804.
Kaasa S, Brenne E, Lund JA, Fayers P, Falkmer U, Holmberg M, Lagerlund M, Bruland O. Prospective randomized multicenter trial on single fraction radiotherapy (8 Gy × 1) versus multiple fractions (3 Gy × 10) in the treatment of painful bone metastases. Radiother Oncol 2006; 79: 278–284.
Arnalot PF, Fontanals AV, Galceran JC, Lynd F, Latiesas XS, Dios NR, Castillejo AR, Bassols ML, Galan JL, Conejo IM et al. Randomized clinical trial with two palliative radiotherapy regimens in painful bone metastases: 30 Gy in 10 fractions compared with 8 Gy in single fraction. Radiother Oncol 2008; 89: 150–155.
Ryu MR, Kang KM, Jang HS, Yoon SC, Kim HK, Lee KS, Shin KS. The role of radiation therapy in multiple myeloma. J Korean Cancer Assoc 1995; 27: 630–636.
Yaneva MP, Goranova-Marinova V, Goranov S. Palliative radiotherapy in patients with multiple myeloma. J Balkan Union Oncol 2006; 11: 43–48.
Durie BG, Salmon S. A clinical staging system for multiple myeloma. Correlation of measured myeloma cells mass with presenting clinical features, response to treatment, and survival. Cancer 1975; 36: 842–854.
Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain 1986; 27: 117–126.
Chow E, Doyle M, Li K, Bradley N, Harris K, Hruby G, Sinclair E, Barnes EA, Danjoux C. Mild, moderate or severe pain categorized by patients with cancer with bone metastases. J Palliat Med 2006; 9: 850–854.
Selby & York Palliative Care Team & Pharmacy Group. Palliative Care Analgesic Dose Conversion Chart. 03/2006 Review Date 01/2011. Leeds, UK: York D&T Committee; 2006.
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM et al. The European Organization for Research and Treatment of Cancer QLQ - C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–376.
Stead ML, Brown JM, Velikova G, Kaasa S, Wislİff F, Child JA, Hippe E, Hjorth M, Sezer O, Selby P. Development of an EORTC questionnaire module to be used in health- related quality-of-life assessment for patients with multiple myeloma. Brit J Haematol 1999; 104: 605–611.
Fayers P, Aaronson NK, Bjordal K, Curran D, Bottomley A. EORTC QLQ - C30 Scoring Manual. 3rd ed. Brussels, Belgium: EORTC; 2001.
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 30; 31: 1341–1346.
Chow E, Wu JS, Hoskin P, Coia LR, Bentzen SM, Blitzer PH. International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. Radiother Oncol 2002; 64: 275–280.
Roodman GD. Pathogenesis of myeloma bone disease. Blood Cells Mol Dis 2004; 32: 290–292.
Vakaet LA, Boteberg T. Pain control by ionizing radiation of bone metastasis. Int J Dev Biol Phys 2004; 48: 599–606.
Sze WM, Shelley MD, Held I, Wilt TJ, Mason MD. Palliation of metastatic bone pain: single fraction versus multifraction radiotherapy--a systematic review of randomized trials. Clin Oncol 2003; 15: 345–352.
Wu JS, Wong R, Johnston M, Bezjak A, Whelan T; Cancer Care Ontario Practice Guidelines Initiative Supportive Care Group. Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases. Int J Radiat Oncol Biol Phys 2003; 55: 594–605.
Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 2007; 25: 1423–1436.
Rades D, Dahm-Daphi J, Rudat V, Schulte R, Stalpers LJ, Veninga T, Hoskin PJ. Is short course radiotherapy with high doses per fraction the appropriate regimen for metastatic spinal cord compression in colorectal cancer patients? Strahlenther Onkol 2006; 128: 708–712.
Rades D, Hoskin PJ, Stalpers LJA, Schulte R, Poortmans P, Veninga T, Dahm-Daphi J, Obralic N, Wildfang I, Bahrehmand R et al. Short course radiotherapy is not optimal for spinal cord compression due to myeloma. Int J Radiat Oncol Biol Phys 2006; 64: 1452–1457.
Steenland E, Leer JW, van Houwelingen H, Post WJ, van den Hout WB, Kievit J, de Haes H, Martijn H, Oei B, Vonk E et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol 1999; 52: 101–109.
Zeng L, Chow E, Bedard G, Zhang L, Fairchild A, Vassiliou V, Alm El-Din MA, Jesus-Garcia R, Kumar A, Forges F et al. Quality of life after palliative radiation therapy for patients with painful bone metastases: results of an international study validating the EORTC QLQ - BM22. Int J Radiat Oncol Biol Phys 2012; 84: e337–342.
Caissie A, Zeng L, Nguyen J, Zhang L, Jon F, Dennis K, Holden L, Culleton S, Koo K, Tsao M et al. Assessment of health-related quality of life with the European Organization for Research and Treatment of Cancer QLQ - C15-PAL after palliative radiotherapy of bone metastases. Clin Oncol (R Coll Radiol) 2012; 24: 125–133.
Valesin Filho ES, de Abreu LC, Lima GH, de Cubero DI, Ueno FH, Figueiredo GS, Valenti VE, Monteiro CB, Wajnsztejn R, Fujiki EN et al. Pain and quality of life in patients undergoing radiotherapy for spinal metastatic disease treatment. Int Arch Med 2013; 6: 6.
Sauer N, Leising D, Wild B, Treiber M, Henningsen P, Jakobsen T. Pain and quality of life following palliative radiotherapy of bone metastases. Strahlenther Onkol 2006; 182: 550–556.